First Circuit Rejects Bid to Require Medicare to Cover Drug That Treats Iron Deficiency
- October 02, 2020
The First Circuit refused September 30 to direct the Centers for Medicare & Medicaid Services (CMS) to allow Medicare Part D reimbursement of Akebia Pharmaceuticals, Inc.’s drug Auryxia, which is used to treat iron deficiency anemia (IDA) in patients with chronic kidney disease.
ARTICLE TAGS
You must be logged in to access this content.